Fractionated Stereotactic Radiation Therapy Using Volumetric Modulated Arc Therapy in Patients with Solitary Brain Metastases

Abstract EN

Purpose.

To analyze retrospectively the clinical efficacy and safety for patients treated with fractionated stereotactic radiation therapy (FSRT) using volumetric modulated arc therapy.

Methods.

Between 2016 and 2017, 46 patients with solitary brain metastasis who underwent FSRT consisting of 25-40 Gy/5 fractions were recruited in this study.

All targets within the same course received different prescriptions according to size.

Toxicities were graded according to the Common Terminology Criteria for Adverse Events version 4.0.

Results.

The median follow-up was 11 months (3-53 months).

The 6-month and 12-month local control rate calculated by Kaplan-Meier estimate was, respectively, 95% and 86%.

Tumor diameter<2.5 cm obtained 100% improved 12-month local control rate compared with 66% in those with ≥2.5 cm (P<0.001).

The 12-month local control calculated by Kaplan-Meier estimate was 95% in tumors with >30 Gy treatment and only 60% in tumors with ≤30 Gy treatment (P=0.001).

Multivariate analysis revealed that the prescription dose≤30 Gy resulted in increased local failure (hazard ratio (HR), 0.14 (range, 0.019-0.95; P=.046)).

Grade 3 or worse toxic effects were found in 5 (11%) patients, and no patient experienced surgical resection for symptomatic radioactive necrosis.

Conclusions.

FSRT for solid brain metastasis appears to have the advantages of a high rate of local control with a minimal risk of severe toxicity and deserves application in the clinical practice.